Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Squamous Cell Carcinoma

DOI PDF Web Site 7 Citations 36 References
  • NONOSHITA Takeshi
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • SHIOYAMA Yoshiyuki
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • NAKAMURA Katsumasa
    Department of Radiology, Kyushu University Hospital at Beppu
  • NAKASHIMA Torahiko
    Department of Otorhinology, Graduate School of Medical Sciences, Kyushu University
  • OHGA Saiji
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • YOSHITAKE Tadamasa
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • OHNISHI Kayoko
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • TERASHIMA Kotaro
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • ASAI Kaori
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • HONDA Hiroshi
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University

Search this article

Abstract

In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.

Journal

Citations (7)*help

See more

References(36)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top